AlphAIalphai — Financial news for AI agents
StockNASDAQ · US · USDFinancial Services · ASSET MANAGEMENT

$CYPH

CYPHERPUNK TECHNOLOGIES INC.

Insider trades
Price · $CYPHvia TradingView
AI sentiment · 7d2 articles
AUG 8net (bullish − bearish)AUG 14
Bullish
2
Neutral
0
Bearish
0
Insider · 30dAll trades →

No SEC Form 4 filings for $CYPH in the last 30 days.

See all $CYPH insider activity →
Top stories · $CYPHMore →
AUG 12·prnewswire.comMed

Cypherpunk Technologies Reports Second Quarter 2026 Financial Results

Cypherpunk Technologies (Nasdaq: CYPH) reported Q2 2026 results for the quarter ended June 30, 2026. It said Zcash (ZEC) treasury holdings rose to 323,394.38 ZEC, with an average purchase price of $341.83. Net income was $39.4M, or $0.18/share, vs a $16.6M net loss in Q2 2025. Leap Therapeutics said it reached FDA alignment on a registrational Phase 3 for sirexatamab in DKK1-high mCRC and initiated a strategic process for the program.

AUG 12·SEC EDGAR 8-K

CYPHERPUNK TECHNOLOGIES INC. (CYPH): Results of Operations and Financial Condition

CYPHERPUNK TECHNOLOGIES INC. (CYPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622925d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cypherpunk Technologies Reports Second Quarter 2026 Financial Results Cambridge, Mass. – August 12, 2026 – Cypherpunk Technologies Inc., (Nasdaq: CYPH) ("Cypherpunk"), today reported financial results for the second quart

JUN 22·SEC EDGAR 8-K

CYPHERPUNK TECHNOLOGIES INC. (CYPH): Submission of Matters to a Vote of Security Holders

CYPHERPUNK TECHNOLOGIES INC. (CYPH) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001509745 0001509745 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

CYPH sentiment & insider activity

Over the past 7 days, alphai's AI scored 2 news stories mentioning CYPH (CYPHERPUNK TECHNOLOGIES INC.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.

Recent CYPH coverage spans earnings, financial news and corporate actions.

What's driving CYPH

  • The quarter’s earnings swing is explicitly tied to ZEC price appreciation and treasury size, making CYPH’s near-term fundamentals sensitive to crypto volatility.

    prnewswire.com · Aug 12, 2026

  • The filing combines an earnings datapoint with a potentially material clinical/regulatory pathway update via its Leap subsidiary, while also highlighting mark-to-market sensitivity to ZEC.

    SEC EDGAR 8-K · Aug 12, 2026

  • Routine shareholder-meeting outcomes; likely limited incremental impact beyond confirming governance items for CYPH.

    SEC EDGAR 8-K · Jun 22, 2026

  • The director's acquisition of 168,750 shares via RSU settlement suggests confidence in the company's future prospects. This insider activity is generally viewed positively, potentially signaling management's belief in the company's value.

    Stock Titan · Mar 18, 2026

  • Cypherpunk Technologies has increased its Zcash holdings, indicating institutional interest and potential bullish sentiment for Zcash (ZEC). The rise in ZEC price by 31% aligns with this activity.

    Decrypt.co · Nov 19, 2025

alphai scores every news story that mentions CYPH with an AI model for sentiment and relevance, and aggregates insider trades from CYPHERPUNK TECHNOLOGIES INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CYPH

Score
AUG 12$CYPHMedAI 8/10prnewswire.com

Cypherpunk Technologies Reports Second Quarter 2026 Financial Results

Cypherpunk Technologies (Nasdaq: CYPH) reported Q2 2026 results for the quarter ended June 30, 2026. It said Zcash (ZEC) treasury holdings rose to 323,394.38 ZEC, with an average purchase price of $341.83. Net income was $39.4M, or $0.18/share, vs a $16.6M net loss in Q2 2025. Leap Therapeutics said it reached FDA alignment on a registrational Phase 3 for sirexatamab in DKK1-high mCRC and initiated a strategic process for the program.

6 min read
AUG 12$CYPHMedSEC EDGAR 8-K

CYPHERPUNK TECHNOLOGIES INC. (CYPH): Results of Operations and Financial Condition

CYPHERPUNK TECHNOLOGIES INC. (CYPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622925d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cypherpunk Technologies Reports Second Quarter 2026 Financial Results Cambridge, Mass. – August 12, 2026 – Cypherpunk Technologies Inc., (Nasdaq: CYPH) ("Cypherpunk"), today reported financial results for the second quart

5 min read
JUN 22$CYPHLowSEC EDGAR 8-K

CYPHERPUNK TECHNOLOGIES INC. (CYPH): Submission of Matters to a Vote of Security Holders

CYPHERPUNK TECHNOLOGIES INC. (CYPH) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001509745 0001509745 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

2 min read
MAR 18$CYPHMedStock Titan

RSU settlements give Cypherpunk (CYPH) director 168,750 common shares

Cypherpunk Technologies Inc. director Richard Christian M acquired 168,750 common shares through the settlement of restricted stock units (RSUs) on March 13, 2026. These RSUs, granted in November and December 2025, converted on a one-for-one basis into common stock for no cash consideration, representing a compensation-related conversion rather than open-market purchases or sales. Following these transactions, the director directly holds 168,750 shares of common stock.

2 min read

Related tickers

More in ASSET MANAGEMENT